Millendo Therapeutics, Inc. Contracts & Agreements
141 Contracts & Agreements
- Business Finance (32 contracts)
- Business Operations (3)
- Human Resources (54)
- Intellectual Property (11)
- Mergers & Acquisitions (3)
- Real Estate (7)
- Uncategorized (31)
- Amendment No. 1, dated as of October 9, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A.,... (Filed With SEC on October 10, 2024)
- Open Market Sale AgreementSM by and among the Company and the Agent, dated June 20, 2024 (Filed With SEC on June 20, 2024)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 19, 2024)
- Second Amendment to Loan and Security Agreement, dated November 3, 2023, by and among Oxford Finance LLC, Tempest Therapeutics, Inc., Tempest TX, Inc. and Millendo Therapeutics... (Filed With SEC on March 19, 2024)
- Separation and Consulting Agreement by and between the Registrant and Tom Dubensky, Ph.D., dated September 15, 2023 (Filed With SEC on November 8, 2023)
- Rights Agreement, dated as of October 10, 2023, between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as... (Filed With SEC on October 11, 2023)
- Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan (Filed With SEC on August 10, 2023)
- Form of Option Grant Package under the Amended and Restated 2023 Equity Incentive Plan (Filed With SEC on August 10, 2023)
- Tempest Therapeutics, Inc. 2023 Inducement Plan (Filed With SEC on August 10, 2023)
- Form of Option Grant Package under the 2023 Inducement Plan (Filed With SEC on August 10, 2023)
- First Amendment to Loan and Security Agreement, dated December 23, 2022, by and among Oxford Finance LLC, Tempest Therapeutics, Inc., Tempest TX, Inc. and Millendo Therapeutics... (Filed With SEC on December 29, 2022)
- Written Agreement & Consent of Warrant Holders and Tempest Therapeutics, Inc (Filed With SEC on November 8, 2022)
- Agreement for Termination of Lease and Voluntary Surrender of Premises (Filed With SEC on August 15, 2022)
- Tempest Therapeutics, Inc. Amended and Restated 2019 Equity Incentive Plan (Filed With SEC on June 21, 2022)
- Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan (Filed With SEC on June 21, 2022)
- Executive Employment Agreement, dated January 12, 2022, by and between the Company and Stephen Brady (Filed With SEC on May 13, 2022)
- Executive Employment Agreement, dated January 12, 2022, by and between the Company and Thomas Dubensky (Filed With SEC on May 13, 2022)
- Executive Employment Agreement, dated January 12, 2022, by and between the Company and Samuel Whiting, M.D., Ph.D (Filed With SEC on May 13, 2022)
- Executive Employment Agreement, dated January 12, 2022, by and between the Company and Nicholas Maestas (Filed With SEC on May 13, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on May 2, 2022)
- Securities Purchase Agreement, dated April 26, 22, by and among Tempest Therapeutics, Inc. and the persons party thereto (Filed With SEC on May 2, 2022)
- Registration Rights Agreement, dated April 26, 22, by and among Tempest Therapeutics, Inc. and the persons party thereto (Filed With SEC on May 2, 2022)
- Form of Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on March 29, 2022)
- Sales Agreement, dated July 23, 2021, between the Company and Jefferies LLC (Filed With SEC on July 23, 2021)
- Form of Indemnification Agreement (Filed With SEC on July 7, 2021)
- Employment Agreement, dated July 7, 2021, by and between the Company and Stephen Brady (Filed With SEC on July 7, 2021)
- Employment Agreement, dated July 7, 2021, by and between the Company and Thomas Dubensky, Ph.D (Filed With SEC on July 7, 2021)
- Employment Agreement, dated July 7, 2021, by and between the Company and Samuel Whiting, M.D., Ph.D (Filed With SEC on July 7, 2021)
- Executive Chair Agreement, by and between Millendo Therapeutics US, Inc. and Julia C. Owens, Ph.D., dated January 27, 2021 (Filed With SEC on March 29, 2021)
- Separation from Employment, by and between Millendo Therapeutics US, Inc. and Julia C. Owens, Ph.D., dated January 27, 2021 (Filed With SEC on March 29, 2021)
- Amended and Restated Employment Agreement between Louis Arcudi III and Millendo Therapeutics US, Inc., dated as of January 27, 2021 (Filed With SEC on March 29, 2021)
- Amended and Restated Employment Agreement between Jennifer Minai-Azary and Millendo Therapeutics US, Inc., dated of January 27, 2021 (Filed With SEC on March 29, 2021)
- Agreement and Plan of Merger, dated as of March 29, 2021, by and among Millendo Therapeutics, Inc., Mars Merger Corp. and Tempest Therapeutics, Inc (Filed With SEC on March 29, 2021)
- Form of Tempest Support Agreement (Filed With SEC on March 29, 2021)
- Form of Millendo Support Agreement (Filed With SEC on March 29, 2021)
- Form of Lock-Up Agreement (Filed With SEC on March 29, 2021)
- Separation Agreement, by and among Millendo Therapeutics, Inc. and Ryan K. Zeidan, dated January 25, 2021 (Filed With SEC on January 28, 2021)
- Amendment to the Millendo Therapeutics, Inc. (formerly OvaScience, Inc.) 2012 Stock Incentive Plan (Filed With SEC on June 23, 2020)
- Amendment to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on June 23, 2020)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 11, 2020)
- Form of Inducement Nonqualified Stock Option Agreement subject to the terms of the OvaScience 2012 Stock Incentive Plan (Filed With SEC on March 11, 2020)
- Form of Stock Option Agreement under the Sub Plan for French Residents under 2019 Equity Incentive Plan (Filed With SEC on March 11, 2020)
- Form of Inducement Nonqualified Stock Option Agreement subject to the terms of the 2019 Equity Incentive Plan (Filed With SEC on March 11, 2020)
- Lease Agreement, by and between Millendo Therapeutics, Inc. and Ann Arbor Real Estate Group, L.L.C., dated October 22, 2018 (Filed With SEC on March 11, 2020)
- Employment Agreement between Christophe Arbet-Engels and Millendo Therapeutics US, Inc., dated as of February 5, 2020 (Filed With SEC on March 11, 2020)
- Amended and Restated Equity Distribution Agreement, dated March 4, 2020, by and among the Company, Citigroup Global Markets Inc. and SVB Leerink LLC (Filed With SEC on March 4, 2020)
- Underwriting Agreement, dated December 4, 2019 (Filed With SEC on December 5, 2019)
- Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Ryan Zeidan, dated August 16, 2019 (Filed With SEC on November 13, 2019)
- Employment Agreement, by and between Millendo Therapeutics US, Inc. and Tamara Joseph, dated July 11, 2019 (Filed With SEC on November 13, 2019)
- Consulting Agreement, by and between the Registrant and Jeffery Brinza, dated August 23, 2019 (Filed With SEC on November 13, 2019)
- Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Julia C. Owens, Ph.D., dated June 19, 2019 (Filed With SEC on August 12, 2019)
- Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Louis Arcudi III, dated June 19, 2019 (Filed With SEC on August 12, 2019)
- Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Jeffery M. Brinza, dated May 23, 2019 (Filed With SEC on August 12, 2019)
- Form of Option Grant Package under 2019 Equity Incentive Plan (Filed With SEC on August 12, 2019)
- Form of RSU Grant Package under 2019 Equity Incentive Plan (Filed With SEC on August 12, 2019)
- License Agreement, by and among F. Hoffmann-La Roche Ltd, Hoffman-La Roche Inc. and Millendo Therapeutics, Inc., dated October 16, 2018 (Filed With SEC on August 12, 2019)
- 2019 Equity Incentive Plan (Filed With SEC on June 13, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on June 13, 2019)
- Lease Agreement (Filed With SEC on April 17, 2019)
- Form of Stock Option Agreement under the Sub Plan for French Residents to the Millendo Therapeutics, Inc. 2012 Stock Plan, as amended (Filed With SEC on April 1, 2019)
- Millendo Therapeutics, Inc. 2012 Stock Incentive Plan, as amended (Filed With SEC on April 1, 2019)
- Form of Stock Option Agreement under the Millendo Therapeutics, Inc. 2012 Stock Incentive Plan (Filed With SEC on April 1, 2019)
- Lease Agreement (Filed With SEC on February 7, 2019)
- Amended and Restated Lease Extension and Modification Agreement (Filed With SEC on February 7, 2019)
- Form of Indemnity Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on December 13, 2018)
- Sub Plan for French Residents to the Millendo Therapeutics, Inc. 2012 Stock Plan, as amended (Filed With SEC on December 13, 2018)
- Sublease Agreement by and between OvaScience, Inc. and Axial Biotherapeutics, Inc., dated as of December 5, 2018 (Filed With SEC on December 6, 2018)
- Separation Agreement by and between OvaScience, Inc. and Christopher A. Kroeger, M.D., M.B.A., dated as of December 5, 2018 (Filed With SEC on December 6, 2018)
- Separation Agreement by and between OvaScience, Inc. and Jonathan Gillis, C.P.A., dated as of December 5, 2018 (Filed With SEC on December 6, 2018)
- Separation Agreement by and between OvaScience, Inc. and James Lillie, Ph.D., dated as of December 5, 2018 (Filed With SEC on December 6, 2018)
- First Amendment to Stock Purchase Agreement, dated as of November 28, 2018, by and among OvaScience, Inc., the purchasers set forth on Schedule I thereto and Millendo... (Filed With SEC on November 30, 2018)
- Employment Terms between Louis Arcudi III and Millendo Therapeutics, Inc., dated as of November 1, 2018 (Filed With SEC on November 26, 2018)
- First Amendment to Agreement and Plan of Merger and Reorganization, dated as of August 8, 2018, by and among OvaScience, Inc., Merger Sub, Inc. and Millendo Therapeutics, Inc.,... (Filed With SEC on November 9, 2018)
- Second Amendment to Agreement and Plan of Merger and Reorganization, dated November 1, 2018, by and among OvaScience, Inc., Orion Merger Sub, Inc. and Millendo Therapeutics, Inc (Filed With SEC on November 1, 2018)
- Stock Purchase Agreement, dated as of November 1, 2018, by and among OvaScience, Inc., the purchasers set forth on Schedule I thereto and Millendo Therapeutics, Inc (Filed With SEC on November 1, 2018)
- Registration Rights Agreement, dated as of November 1, 2018, by and among OvaScience, Inc. and the investors listed on Schedule A thereto (Filed With SEC on November 1, 2018)
- Amended and Restated License Agreement, by and between Millendo Therapeutics, Inc. and the Regents of the University of Michigan, dated November 9, 2015 (Filed With SEC on September 26, 2018)
- Nonstatutory Stock Option Agreement, dated March 6, 2018, by and between the Registrant and James W. Lillie, Ph.D (Filed With SEC on May 3, 2018)
- Exclusive License Agreement, dated June 27, 2011, between the Registrant and The General Hospital Corporation (Filed With SEC on May 3, 2018)
- Amendment No. 1 to the Exclusive License Agreement dated September 7, 2011, between the Registrant and the General Hospital Corporation (Filed With SEC on May 3, 2018)
- Termination Agreement, dated as of April 30, 2018, by and between the Registrant and Dr. Michelle Dipp (Filed With SEC on May 3, 2018)
- Amended and Restated Exclusive License Agreement, dated November 6, 2017, between the Registrant and The General Hospital Corporation (Filed With SEC on March 15, 2018)
- Nonstatutory Stock Option Agreement, dated June 21, 2017, between the Registrant and Christopher A. KroegerOffer Letter, dated January 2, 2018, between the Registrant and James... (Filed With SEC on March 15, 2018)
- Nonstatutory Stock Option Agreement, dated as of June 21, 2017, by and between the Registrant and Christopher A. Kroeger (Filed With SEC on November 2, 2017)
- Exhibit A Definitions (Filed With SEC on August 3, 2017)
- [Signature Page Follows] (Filed With SEC on March 2, 2017)
- [Signature Page Follows] (Filed With SEC on March 2, 2017)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement (Filed With SEC on November 3, 2016)
- Exhibit 10.3 (Filed With SEC on November 3, 2016)
- Exhibit A Definitions (Filed With SEC on September 6, 2016)
- OVASCIENCE, INC. 7,150,00 Shares of Common Stock Underwriting Agreement (Filed With SEC on May 26, 2016)
- [Signature Page Follows] (Filed With SEC on May 5, 2016)
- Exhibit A Definitions (Filed With SEC on May 5, 2016)
- Appendix Homeworking (Filed With SEC on May 5, 2016)
- OVASCIENCE, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan (Filed With SEC on May 5, 2016)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan (Filed With SEC on May 5, 2016)
- OVASCIENCE, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Companys 2012 Stock Incentive Plan (Filed With SEC on May 5, 2016)
- Exhibit A Definitions (Filed With SEC on May 5, 2016)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement (Filed With SEC on May 5, 2016)
- INDEPENDENT CONSULTING AGREEMENT (Filed With SEC on May 5, 2016)
- [Signature Page Follows] (Filed With SEC on February 26, 2016)
- Exhibit A Definitions (Filed With SEC on February 26, 2016)
- Appendix Homeworking (Filed With SEC on February 26, 2016)
- NINE FOURTH AVENUE WALTHAM, MASSACHUSETTS LABORATORY BUILDING LEASE Tenant: OvaScience, Inc. Landlord: Nine Fourth Avenue LLC TABLE OF CONTENTS (Filed With SEC on August 10, 2015)
- THE GENERAL HOSPITAL CORPORATION EXCLUSIVE LICENSE AGREEMENT MGH Agreement No: A209968 MGH Case Nos: 02595 and 21131 (Filed With SEC on May 11, 2015)
- Amendment No. 1 To The Exclusive License Agreement (Filed With SEC on May 11, 2015)
- OVASCIENCE, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. Restricted Stock Unit Agreement (Time-Based) Granted under 2012 Stock Incentive Plan NOTICE OF GRANT (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. Restricted Stock Unit Agreement (Performance-Based) Granted under 2012 Stock Incentive Plan NOTICE OF GRANT (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan (Filed With SEC on March 16, 2015)
- Exhibit A Definitions (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of March 3, 2015) (Filed With SEC on March 16, 2015)
- OVASCIENCE, INC. 2,300,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on January 8, 2015)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement (Filed With SEC on November 10, 2014)
- Exhibit A Definitions (Filed With SEC on September 18, 2014)
- OVASCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on August 7, 2014)
- OVASCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on May 8, 2014)
- OVASCIENCE, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 6, 2014)
- CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 4 TO THE EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 5 TO THE EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on February 27, 2014)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on February 27, 2014)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on February 27, 2014)
- Exhibit A Definitions (Filed With SEC on November 13, 2013)
- OVASCIENCE, INC. Nonstatutory Stock Option Agreement (Filed With SEC on November 13, 2013)
- OvaScience, Inc. (Filed With SEC on November 13, 2013)
- OVASCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective January 1, 2014) (Filed With SEC on November 13, 2013)
- AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT BETWEEN OVASCIENCE, INC. AND (Filed With SEC on November 13, 2013)
- OVASCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on June 13, 2013)
- OVASCIENCE, INC. SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 14, 2013)
- OVASCIENCE, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 14, 2013)
- [Company Letterhead] (Filed With SEC on February 25, 2013)
- Exhibit A Definitions (Filed With SEC on February 25, 2013)
- OVASCIENCE, INC. Restricted Stock Unit Agreement Granted under 2012 Stock Incentive Plan NOTICE OF GRANT (Filed With SEC on February 25, 2013)
- OVASCIENCE, INC. Restricted Stock Unit Agreement Granted under 2012 Stock Incentive Plan NOTICE OF GRANT (Filed With SEC on February 25, 2013)
- OVASCIENCE, INC. SUBSCRIPTION AGREEMENT (Filed With SEC on August 14, 2012)
- OVASCIENCE, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 14, 2012)